IMP321 (eftilagimod alpha)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for IMP321 (eftilagimod alpha), covering 2026-02-19 to 2026-02-19. Get the full timeline:
Most recent: Clinical Trial Update: Feasibility and Safety of IMP321 (Eftilagimod Alpha) for Advanced Stage Solid Tumors [Phase 1]